Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.66 |
| ▸ | RAF1 | P04049 | 6/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990633 | 0.93 | DDR2 (0.56) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL170965 | 0.93 | DDR2 (0.73) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL171181 | 0.91 | DDR2 (0.64) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL15574750 | 0.91 | DDR2 (0.70) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL15573352 | 0.90 | DDR2 (0.73) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL171212 | 0.88 | DDR2 (0.83) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL13603578 | 0.85 | DDR2 (0.63) | DDR2RAF1KDRGSK3BMAPK14 | |
| SCHEMBL16990604 | 0.85 | DDR2 (0.63) | DDR2RAF1CSF1RFLT3TOP2A | |
| SCHEMBL171397 | 0.85 | DDR2 (0.83) | DDR2RAF1CSF1RFLT3KDR | |
| SCHEMBL171330 | 0.84 | DDR2 (0.71) | DDR2RAF1CSF1RFLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | claimed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | DDR2 4558/4885RAF1 2/4885CSF1R 2298/4885 |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885RAF1 3072/4885CSF1R 885/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | DDR2 4558/4885RAF1 2/4885CSF1R 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.